PTC/SB/08s (08-03)
Approved for use through 97/31/2006, ONE 0651-0231
U.S. Platent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

	Application Number			
	Filing Date			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Chika		hikashi Sato	
( Not for submission under 37 CFR 1.99)	Art Unit		N/A	
	Examiner Name	N/A		
	Attorney Docket Number		KIN-16867	

	U.S.PATENTS				Remove					
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>			Releva	Columns,Lines wh int Passages or Re s Appear			
	1	4804367		1989-0	2-14	Smith et al.				
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applicant Rele		Releva	ages,Columns,Lines where blevant Passages or Relevant gures Appear	
	1									
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d button	Add	
				FOREIG	SN PAT	TENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lin where Relevant Passages or Releva Figures Appear	74
	1	58-190450	JP			1983-11-07	Saul Leibinsohn			
	2	08-033710	JP			1996-02-06	Kawasumi Lab Inc		English abstract included	
	3	2002-239002	JP			2002-08-27	Sanguroo.KK		English abstract	

	Application Number		
NEODWATION DIGGI COURT	Filing Date		
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Chika	ashi Sato
Not for submission under 37 CFR 1.99)	Art Unit		N/A
,	Examiner Name	N/A	
	Attornou Docket Number		KIN-16867

If you wish	h to a	dd add	ditional Foreign Patent Document citation information please click the Add button Add	_
			NON-PATENT LITERATURE DOCUMENTS Remove	_
Examiner Initials*	Cite No	(bool	de name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item k, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), sher, city and/or country where published.	T5
	1			
If you wis	h to a	dd add	ditional non-patent literature document citation information please click the Add button Add	_
			EXAMINER SIGNATURE	_
Examiner	Signa	ture	Date Considered	_
*EXAMIN	ER: In	itial if	reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a	Π

Take Kint Code of USPTO Platent Documents at year, USPTO\_GOLY or MEPP 901.6. \* Enter office that issued the document, by the how-letter code (WIPO Standard ST.3.) \*\*For Liganeses petant documents, the decision to the year of the reign or the Engerer runt precision be sent in unbread for high petant document. \*\*Incl of Cournert by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*\*Applicant is to place a check mark here (English Insquages transitions in addition.\*\*)

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# Application Number Filing Date Filing Date

### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make	e the appropriate	e selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.1)

## ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement was called the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement are supported to the filing of the information disclosure statement.

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/David E. Spaw/	Date (YYYY-MM-DD)	2006-09-14
Name/Print	David E. Spaw	Registration Number	34732

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GAD 47 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.